Related Experiment Video
Updated: Apr 19, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Promising targets and current clinical trials in metastatic squamous cell lung cancer
1London Regional Cancer Program, Department of Medical Oncology, London Health Sciences Centre , London, ON , Canada.
Abstract:
Squamous cancer of the lung (SQCC), although no longer the premier variant of non-small cell lung cancer, continues to impose a heavy world-wide burden. Advanced SQCC has enjoyed little of the recent progress benefiting patients with adenocarcinoma of the lung, but that has now begun to change. This article reviews the underlying molecular pathology of SQCC, as well as potential new targets and the corresponding novel targeted agents; included are some of which may soon be approvable in this notoriously hard-to-treat indication.
Insights
New targeted therapies are emerging for squamous cell carcinoma of the lung (SQCC), offering hope for this hard-to-treat cancer. This review covers molecular pathology and novel agents for advanced SQCC.
Area of Science:
- Oncology
- Molecular Pathology
- Drug Discovery
Background:
- Squamous cell carcinoma of the lung (SQCC) remains a significant global health burden.
- Advanced SQCC has historically seen limited therapeutic progress compared to other non-small cell lung cancers.
- Recent advancements indicate a potential shift in treatment paradigms for SQCC.
Purpose of the Study:
- To review the molecular pathology of SQCC.
- To identify novel molecular targets for SQCC treatment.
- To discuss emerging targeted agents for advanced SQCC.
Main Methods:
- Literature review of molecular pathology in SQCC.
- Analysis of recent clinical trial data for targeted therapies.
- Identification of potential drug candidates for SQCC.
Main Results:
- Understanding the molecular drivers of SQCC is crucial for developing effective treatments.
- Several novel targeted agents are in development for SQCC.
- Some agents show promise for near-term approval.
Conclusions:
- Targeted therapies are beginning to offer new hope for advanced SQCC.
- Further research into SQCC molecular pathology will drive the development of novel treatments.
- The landscape of SQCC treatment is evolving with new therapeutic options.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies